Cardiovascular disease - DiabetesontheNet

This site is intended for healthcare professionals only

Cardiovascular disease

Filter:

We need to increase our awareness of heart failure in our patients with diabetes

With growing evidence that SGLT2 inhibitors can improve heart failure-related outcomes, Su Down argues the need to increase healthcare professional awareness of heart failure and routinely discuss it with patients.

Lowering LDL-cholesterol reduces CV event risk in diabetic dyslipidaemia

Renoprotection for patients with diabetes and kidney disease

Canagliflozin is cardioprotective in diabetic kidney disease

Semaglutide reduces cardiovascular risk in type 2 diabetes

Hypoglycaemia increases risk of adverse events in older patients with dementia

Practitioner empathy impacts long-term diabetes outcomes

Patients and doctors value empathy. Empathetic care encompasses shared decision making and understanding the patient’s perspective as well as an appreciation of the broader context in which the patient’s illness is experienced. Patients from 49 English general practices were invited to assess practitioner empathy and their experiences of diabetes care in the 12 months since their diagnosis. Higher empathy scores were associated with lower risks of cardiovascular disease events and all-cause mortality.

How to manage hyperglycaemia in people with severe mental illness

An overview of the information needed to screen, monitor and manage hyperglycaemia in those with severe mental illness.

Diabetes Distilled: Behavioural change lowers 10-year cardiovascular and mortality risk

Small changes after a recent diabetes diagnosis reduce cardiovascular and mortality risks.

Diabetes Distilled: Intensive intervention reduces stroke risk in diabetes with microalbuminuria

Steno-2 reveals that treating multiple risk factors reduces cerebrovascular events.

Inter-arm differences in blood pressure: A brief summary

A novel marker of cardiovascular risk: a consideration for primary care?

Behavioural change lowers 10-year cardiovascular and mortality risk

Adults with screen-detected type 2 diabetes, recruited from general practices in Eastern England, were assessed for changes in diet, physical activity and alcohol use in the year following a diabetes diagnosis. They were then followed up for an average of 10 years. Investigators found that, in the year following a diabetes diagnosis, small reductions in alcohol consumption were correlated with a lower hazard of cardiovascular disease and small reductions in calorie intake were associated with a lower hazard of all-cause mortality.

Intensive intervention reduces stroke risk in diabetes with microalbuminuria

Data from the Steno-2 Study were analysed to assess whether multiple risk factor intervention reduced the chance of stroke in individuals with type 2 diabetes and microalbuminuria. Participants were randomly allocated to intensified or conventional multifactorial intervention targeting classical cardiovascular disease risk factors. Post hoc analysis showed that the risk of stroke and number of recurrent cerebrovascular events were reduced with intensified multiple risk factor intervention in patients with type 2 diabetes and microalbuminuria.

Updates from the 2019 ADA meeting

News of the most important trial results for diabetes care from the 79^th Scientific Sessions of the American Diabetes Association.

Oral semaglutide significantly reduces cardiovascular events

An outcome study for oral semaglutide has evaluated the drug’s cardiovascular safety against placebo when added to standard care. Semaglutide is an injectable incretin that has recently become available; oral semaglutide has not yet been approved by the European Medicines Agency. Results showed no significant difference in three-point major adverse cardiac events, but there was a significant reduction in cardiovascular death and all-cause mortality with oral semaglutide.

No additional cardiovascular risk with linagliptin

The CARdiovascular Outcome Study of LINAgliptin versus glimepiride in patients with type 2 diabetes (CAROLINA) trial is the last planned cardiovascular outcome trial on a dipeptidyl peptidase 4 inhibitor. Researchers found that there were no substantial differences in cardiovascular events between linagliptin and glimepiride, although they found a significantly higher risk of hypoglycaemia and modest weight gain in the glimepiride group.

Atrial fibrillation: Risk factors and comorbidities

A plea for clinicians to screen for and identify this potentially devastating comorbidity, which can easily be done routinely in diabetes reviews.

SGLT2 inhibitors – moving on with the evidence

An updated review of the benefits and difficulties associated with the use of SGLT2 inhibitors.

Resources

For the latest news and articles

Sign up to all DiabetesontheNet journals

Follow us for all the latest news and updates in diabetes.

Resources

Journals

Useful information

© Copyright Omniamed Communications. All Rights Reserved
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom

;